Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. Ann Oncol. 2009;20(1):5–16., , .
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001;345(15):1091–1097., , .
Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71–96., , .
Colorectal cancer: can we lower the death rate in the 1990s?Can Fam Physician. 1993;39:107–114., .
homepage. Available at: http://seer.cancer.gov/.
Colon cancer in older adults. Semin Oncol. 2008;35(6): 561–568., , .
Chemotherapy in elderly patients with colorectal cancer. Oncologist. 2008;13(4):390–402., , .
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16): 2938–2947., , .
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343(13):905–914., , .
Current treatment strategies in elderly patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2007;6(7):508–515., , .
Representation of older patients in cancer treatment trials. Cancer. 1994;74(7 suppl): 2208–2214., , .
Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol. 2005;23(13):3112–3124., , .
Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. Cancer. 2007;110(7):1611–1620., , .
Recent major progress in long-term cancer patient survival disclosed by modeled period analysis. J Clin Oncol. 2007;25(22):3274–3280., , .
Trends in the management and survival of digestive tract cancers among patients aged over 80 years. Ailment Pharmacol Ther. 2005;22:233–241., , .
Managing older patients with colorectal cancer. J Clin Oncol. 2007;25(14):1891–1897., , .
Long overdue: phase II studies in older cancer patients: where does the FDA stand?J Clin Oncol. 2008; 26(8):1387–1388., , .
At what age should we discontinue colon cancer screening in the elderly?Cleve Clin J Med. 2007;74(4):269–272., .
American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001 – testing for early lung cancer detection. CA Cancer J Clin. 2001;51(1):38–75; quiz 77–80., , .
Screening for colorectal cancer: recommendation and rationale. Ann Intern Med. 2002;137(2): 129–131.
Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149(9):627–637..
Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin. 2009;59(1):27–41., , .
Increase in screening for colorectal cancer in older Americans: results from a national survey. J Am Geriatr Soc. 2008;56(8):1511–1516., , .
Preventive health care for older patients. Prim Care. 2002;29(3):599–614., .
Screening for colorectal, breast, and cervical cancer in the elderly: a review of the evidence. Am J Med. 2005;118(10):1078–1086., , .
Colorectal cancer screening in elderly patients: when should be more useful?Cancer Treat Rev. 2007;33(6): 528–532., .
Screening colonoscopy in very elderly patients: prevalence of neoplasia and estimated impact on life expectancy. J Am Med Assoc. 2006;295(20): 2357–2365., , .
Risk of perforation after colonoscopy and sigmoidoscopy: a population-based study. J Natl Cancer Inst. 2003;95(3):230–236., , .
Natural history of untreated colonic polyps. Gastroenterology. 1987;93(5):1009–1013., , .
Cancer screening in elderly patients: a framework for individualized decision making. J Am Med Assoc. 2001;285(21): 2750–2756., .
Colonoscopy in the elderly: low risk, low yield in asymptomatic patients. Dis Colon Rectum. 2006;49(5):646–651., , .
First-line treatment strategies for elderly patients with metastatic colorectal cancer. Drugs Aging. 2007;24(3): 223–238., .
Outcome of surgery for colorectal cancer in a defined population in Sweden from 1984 to 1986. Dis Colon Rectum. 1995;38(6):645–650., , .
The influence of age on resection rates and postoperative mortality in 6457 patients with colorectal cancer. Int J Colorectal Dis. 1996;11(1): 45–48., , .
Surgery for colorectal cancer in elderly patients: a systematic review. Colorectal Cancer Collaborative Group. Lancet. 2000;356(9234): 968–974.
Favorable short-term and long-term outcome after elective radical rectal cancer resection in patients 75 years of age or older. Dis Colon Rectum. 2000;43(12):1704–1709., , .
Colorectal cancer in the elderly: is there a role for safe and curative surgery?ANZ J Surg. 2008;78(6):466–470., , .
Colorectal cancer in the elderly: surgical treatment and long-term survival. Int J Colorectal Dis. 2008;23(6):601–610., , .
What predicts serious complications in colorectal cancer resection?Am Surg. 2003;69(11):969–974., , .
Surgical outcomes for colorectal cancer patients including the elderly. Hepatogastroenterology. 2001;48(38): 440–444., , .
Incidence and patterns of recurrence after resection for cure of colonic cancer in a well defined population. Br J Surg. 2006;93(9): 1115–1122., , .
Preexisting disease as a predictor of the outcome of colectomy. Am J Surg. 1991;162(5):497–498., .
Surgical treatment of liver metastases from colorectal cancer in elderly patients. Int J Colorectal Dis. 2007;22(1):77–83., , .
Outcomes after major hepatectomy in elderly patients. J Am Coll Surg. 2006;203(5):677–683., , .
Liver resection for colorectal liver metastases in older patients. Crit Rev Oncol Hematol. 2008;67(3):273–278., , .
Use of surgery among elderly patients with stage IV colorectal cancer. J Clin Oncol. 2004;22(17): 3475–3484., , .
Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. A SIOG surgical task force prospective study. Crit Rev Oncol Hematol. 2008;65(2):156–163., , .
Pre-operative assessment of cancer in the elderly (PACE): a comprehensive assessment of underlying characteristics of elderly cancer patients prior to elective surgery. Surg Oncol. 2006;15(4):189–197., , .
Rectal cancer. Crit Rev Oncol Hematol. 2009;70(2):160–182., , .
The efficacy of preoperative 5-fluorouracil, high-dose leucovorin, and sequential radiation therapy for unresectable rectal cancer. Cancer. 1993;71(11): 3486–3492., , .
Preoperative combined modality treatment for rectal cancer. Oncology. 1994;8(5):53–58, 61; discussion 61, 64–68.
Swedish Rectal Cancer Trial. N Engl J Med. 1997;336(14):980–987..
Ageism in rectal carcinoma? Treatment and outcome variations. Int J Gastrointest Cancer. 2002;32(2–3):129–138., , .
Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol. 2005;23(24): 5644–5650., , .
Are survival rates different for young and older patients with rectal cancer?Dis Colon Rectum. 2004;47(12):2064–2069., , .
Acute side effects and complications after short-term preoperative radiotherapy combined with total mesorectal excision in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol. 2002;20(3):817–825., , .
Short-course preoperative radiotherapy with delayed surgery in rectal cancer – a retrospective study. Radiother Oncol. 2008;87(3):343– 349., , .
Preoperative short-term radiation therapy (25 Gy, 2.5 Gy twice daily) for primary resectable rectal cancer (phase II). Br J Cancer. 2005;92(7): 1209–1214., , .
Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol. 2004;22(18):3766–3775., , .
Adjuvant therapy for patients with colon and rectal cancer. J Am Med Assoc. 1990;264(11):1444–1450..
Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322(6):352–358., , .
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343–2351., , .
Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol. 2003;21(7):1293–1300., , .
Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. J Am Med Assoc. 2005;294(21): 2703–2711., , .
Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst. 2001;93(11): 850–857., , .
Rates and predictors of chemotherapy use for stage III colon cancer: a systematic review. Cancer. 2008;113(12):3279–3289., ,
The impact of chronic illnesses on the use and effectiveness of adjuvant chemotherapy for colon cancer. Cancer. 2007;109(12):2410–2419., , .
Completion of therapy by Medicare patients with stage III colon cancer. J Natl Cancer Inst. 2006;98(9):610–619., , .
United States life tables, 2004. Natl Vital Stat Rep. 2007;56(9):1–39.
Adjuvant therapy in the elderly: making the right decision. J Clin Oncol. 2007;25(14):1870–1875., , .
Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol. 2005;23(34):8671–8678., , .
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370(9604):2020–2029., , .
Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?J Clin Oncol. 2004;22(10):1797–1806., , .
Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colon carcinoma: a 10-year experience of the Geisinger Medical Center. Cancer. 2002;94(7):1931–1938., , .
Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol. 1999;17(8): 2412–2418., , .
Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med. 2002;136(5):349–357., , .
Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer. J Clin Oncol. 2002;20(19):3992–3998., .
Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol. 1998;16(1):295–300., , .
Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol. 2006;24(15):2368–2375., , .
Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352(26): 2696–2704., , .
New chemotherapeutic advances in pancreatic, colorectal, and gastric cancers. Oncologist. 2004;9(3):282–294.
Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients. Cancer Chemother Pharmacol. 2002;49(3):225–234., , .
Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer. J Clin Oncol. 2005;23(21):4719–4725., , .
A retrospective study of coagulation abnormalities in patients receiving concomitant capecitabine and warfarin. Clin Colorectal Cancer. 2006;5(5):354–358., , .
An observational study examining the impact of capecitabine on warfarin antithrombotic activity and bleeding complications. Curr Med Res Opin. 2006;22(2):307–314., , .
Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol. 2006;24(25):4085–4091., , .
Disparities in the use of chemotherapy and monoclonal antibody therapy for elderly advanced colorectal cancer patients in the community oncology setting. Oncologist. 2008;13(8):876–885., , .
Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. Br Med J. 2000;321(7260): 531–535.
Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol. 2004;15(9):1330–1338., , .
First-line chemotherapy with fluorouracil and folinic acid for advanced colorectal cancer in elderly patients: a phase II study. J Clin Gastroenterol. 2003;36(3): 228–233., , .
Advanced colorectal cancer in elderly patients: tolerance and efficacy of leucovorin and fluorouracil bolus plus continuous infusion. Anticancer Res. 2001;21(1A): 489–492., , .
Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998;352(9138):1413–1418., , .
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 1998;352(9138):1407–1412., , .
A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer. 1999;85(4): 786–795., , .
Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. Br J Cancer. 2004;91(8):1453– 1458., , .
Single-agent irinotecan as second-line weekly chemotherapy in elderly patients with advanced colorectal cancer. Tumori. 2006;92(4):290–294., .
Irinotecan in the treatment of colorectal cancer. Cancer Treat Rev. 2006;32(7):491–503., , .
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol. 2007;25(30):4779–4786., , .
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22(1):23–30., , .
Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol. 2008;26(9):1443–1451., , .
Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. J Clin Oncol. 2005;23(15):3545–3551., , .
Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial. Oncology. 2005;69(5):384–390., , .
Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials. Ann Oncol. 2004;15(7):1013– 1017., , .
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355(9209): 1041–1047., , .
Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol. 2005;23(22):4856– 4865., , .
Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A128 genotype screening: a double-blind, randomized, placebo-controlled study. Oncologist. 2006;11(8): 944–954., , .
Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol. 2009;27(8):1243–1249., , .
Oxaliplatin-related neurotoxicity: how and why?Crit Rev Oncol Hematol. 2006;59(2):159–168., , .
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol. 2003;21(11): 2059–2069., , .
FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study. Cancer. 2007;110(12):2666–2671., , .
High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer. Ann Oncol. 2005;16(7): 1147–1151., , .
Reduced dose intensity FOLFOX-4 as first line palliative chemotherapy in elderly patients with advanced colorectal cancer. J Kor Med Sci. 2005;20(5): 806–810., , .
Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study. J Clin Oncol. 2005;23(13):3104–3111., , .
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol. 2002;13(4):566–575., , .
Treatment of colorectal cancer in the elderly: a review of the literature. Cancer Treat Rev. 2006;32(1):1–8., , .
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008;26(12):2006–2012., , .
XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer. 2006;94(7):969–975., , .
Capecitabine (Cap) and oxaliplatin (Ox) in elderly and/or frail patients with metastatic colorectal cancer: the FOCUS2 trial [abstract]. J Clin Oncol. 2007;25(suppl):9030., , .
Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer. Crit Rev Oncol Hematol. 2008; 67(3):255–262., , .
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351(4): 337–345., , .
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22(7): 1201–1208., , .
Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357(20):2040–2048., , .
Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer. Crit Rev Oncol Hematol. 2008;67(3):255–262., , .
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(10):1626–1634., , .
Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005;23(16): 3706–3712., , .
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99(16): 1232–1239., , .
Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol. 2009;27(2):199–205., , .
Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol. 2008;26(21):3523–3529., , .
Desire for information and involvement in treatment decisions: elderly cancer patients'; preferences and their physicians'; perceptions. J Clin Oncol. 2007;25(33):5275–5280., , .
Aging, frailty, and chemotherapy. Cancer Control. 2007;14(1):7–12.
Geriatric oncology: a field coming of age. J Clin Oncol. 2007;25(14):1821–1823., , .
Pharmacokinetics and pharmacodynamics in the elderly. Clin Adv Hematol Oncol. 2007;5(3):181–182.
Management of prostate cancer in the older man. Semin Oncol. 2008;35(6):597–617., , .
Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A. 2004;59(3):255–263., , .
The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc. 2001;49(12):1691–1699., , .